Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GK | 28.24 | 0.25 | +0.88% |
| AdvisorShares Gerber Kawasaki ETF (GK) | |||
| REGL | 89.70 | 0.02 | +0.02% |
| ProShares S&P MidCap 400 Dividend Aristocrats ETF (REGL) | |||
| TBFC | 28.68 | N/A | N/A |
| Brinsmere Fund Conservative ETF (TBFC) | |||
| ZJAN | 28.52 | -0.01 | -0.03% |
| Innovator Equity Defined Protection ETF - 1 Yr January | |||
| TSMZ | 7.55 | -0.12 | -1.54% |
| Direxion Daily TSM Bear 1X ETF (TSMZ) | |||
A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with VIR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To RCUS | 1D Price Change % | ||
|---|---|---|---|---|
| RCUS | 100% | -19.58% | ||
| VIR - RCUS | 49% Loosely correlated | -1.58% | ||
| XNCR - RCUS | 49% Loosely correlated | +0.88% | ||
| KURA - RCUS | 46% Loosely correlated | -1.00% | ||
| NRIX - RCUS | 44% Loosely correlated | -0.31% | ||
| BCAX - RCUS | 44% Loosely correlated | -2.40% | ||
More | ||||
a company which offers pre-clinical drug discovery and development solutions
Industry Biotechnology
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 219 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.242) is normal, around the industry mean (2.988). P/E Ratio (-4.848) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.